May 29, 2025

HHS Questions Pediatric Gender Treatment Evidence

HHS review finds weak evidence for puberty blockers, hormones in minors with gender dysphoria, urges protocol updates.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 20, 2025

FDA Releases Guidance to Accelerate Generic Drugs

The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."

Conexiant

May 16, 2025

FDA Clears First Blood Test for Alzheimer’s

The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.

Conexiant

May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

June 12, 2024

USPSTF Releases Draft Osteoporosis Screening Guidelines

The USPSTF's draft recommendations reaffirm osteoporosis screening for older women, call for more research on screening men, and address health disparities.

Conexiant

July 26, 2024

16 U.S. States Reach $86M Settlement with Drug Manufacturer

Indivior, a Virginia-based drug manufacturer, has reached an $86 million settlement with 16 U.S. states over its alleged role in the opioid addiction crisis, involving buprenorphine-based products. The settlement funds will be used for opioid addiction treatment, recovery, and prevention.

Reuters

June 21, 2024

In a First, FDA Approves Flavored E-Cigarettes

'The strength of evidence of benefits to adult smokers from completely switching to a less harmful product was sufficient to outweigh the risks to youth.'

Reuters

June 28, 2024

Medical Professor Charged with Data Manipulation in Alzheimer's Drug Trial

A U.S. medical professor facing fraud charges for submitting false data in Alzheimer's disease research, impacting a publicly-listed pharmaceutical company and raising integrity concerns about its drug development. The case highlights the potential consequences of research misconduct.

Reuters